DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06654219

RecruitingPhase NA

Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia

Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor Agonist Prior to Anesthesia

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Enrollment

136

estimated

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Number of participants that show prevalence of increased RGC determined

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06654219
Org study IDHSC-MS-24-0940

Timeline

Milestones

Study first posted2024-10-23actual
Study start2025-10-30actual
Last update posted2025-11-03actual
Primary completion2026-05-01estimated
Study completion2026-05-01estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists
•Undergoing upper endoscopy only - no colonoscopy due to prep

Exclusion criteria

•Previous gastric resection or bypass
•Gastric band in situ
•Previous fundoplication
•Large hiatal hernia
•Pregnant patients
•Recent trauma
•Inability to turn to the right lateral decubitus position.
•Patients on erythromycin, metoclopramide, domperidone, opioids.
•Gastroparesis previous

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL
3
Other clinical outcomes
1

Patient-reported / QoL

3 endpoints
Secondary/protocol endpoint

Number of participants that show thirst as assessed by the VAS

Time frame:prior to procedure ( within 2 hours before procedure)

descriptive, improvement

Secondary/protocol endpoint

Number of participants that show hunger as assessed by the VAS

Time frame:prior to procedure ( within 2 hours before procedure)

descriptive, improvement

Secondary/protocol endpoint

Number of participants that show anxiety as assessed by the VAS

Time frame:prior to procedure ( within 2 hours before procedure)

descriptive, improvement

Other clinical outcomes

1 endpoint
Primary/protocol endpoint/low confidence

Number of participants that show prevalence of increased RGC determined using preoperative GUS

Time frame:prior to procedure ( within 2 hours before procedure)

threshold achievement, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.